Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE-listed (PHR) patient intake platform digitizing check-in for 4,000+ practices at $383M revenue; pharma-funded activation programs competing with Epic and Clearwave for healthcare front-office engagement.
Phreesia is a Raleigh, North Carolina-based patient intake and engagement platform — listed on NYSE (NYSE: PHR) — providing healthcare practices, health systems, and pharmaceutical companies with digital tools for patient registration, insurance verification, payment collection, clinical pre-screening, and patient activation. Founded in 2005 by Chaim Indig and Evan Roberts and generating $383 million in revenue in fiscal year 2025 (ending January 2025), Phreesia serves 4,000+ healthcare practices and health systems with the patient-facing digital infrastructure that replaces paper clipboards and manual front-desk registration.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.